Clinical trials: Pulmonary Hypertension, Primary
Pulmonary Arterial Hypertension
Bosentan and Pulmonary Endothelial Function
6 months therapy of Bosentan, an endothelin antagonist, will lead to improvement in pulmonary microvascular endothelial function.
- Trial name
- PARBO (NCT01721564)
- Testing
- Bosentan
- Volunteers
- 8 people
- Sponsor
- Prof David S Celermajer
Pulmonary Hypertension, Pulmonary Arterial Hypertension
The Effects of Commercial Air Travel on Patients Suffering From Pulmonary Hypertension
The aim of this study is to 1) descriptively report possible in flight events and 2) to provide regression analysis if the number of events are statistically significant in their prevalence and thus are useful in finding possible…
- Trial name
- PEGASUS (NCT03051763)
- Where
- 5 sites in Germany, Switzerland
- Volunteers
- 1,000 people
- Sponsor
- University of Giessen
Pulmonary Arterial Hypertension
A Study of Treprostinil Palmitil Inhalation Powder (TPIP) In Pulmonary Arterial Hypertension (PAH)
The main purpose of this study is to evaluate the safety and tolerability of single dose of treprostinil palmitil inhalation powder (TPIP) in participants with pulmonary arterial hypertension (PAH).
- Trial name
- NCT04791514
- Testing
- Treprostinil Palmitil
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Insmed Incorporated
Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension
A Clinical Study to Investigate the Long-term Safety of the Drug Macitentan in Patients With Pulmonary Hypertension Who Were Previously Treated With Macitentan in Clinical Studies.
The aim of the trial is to study the long-term safety of macitentan and to provide continued treatment with macitentan to patients with pulmonary arterial hypertension (PAH) and Chronic thromboembolic pulmonary hypertension…
- Trial name
- UMBRELLA (NCT03422328)
- Testing
- macitentan
- Where
- 34 sites in Belarus, Belgium and 5 more
- Volunteers
- 151 people
- Sponsor
- Actelion
Allogeneic Stem Cell Transplantation, Lung Allograft Transplantation
Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging
Background: Injury or diseases of the heart and lung can sometimes cause scar tissue (fibrosis) to build up in those organs. Current imaging scans can see this scar tissue once it has formed, but researchers want to find a way to…
- Conditions
- Allogeneic Stem Cell Transplantation, Lung Allograft Transplantation, Interstitial Lung Disease, Acute Lung Injury
- Trial name
- NCT07613099
- Testing
- [18F]FAPI-74, 18F-FAPI-74 PET/CT Imaging
- Where
- United States
- Volunteers
- 210 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Pulmonary Arterial Hypertension
Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension
The purpose of this study was to explore the efficacy and safety of LTP001 in participants with pulmonary arterial hypertension (PAH) to determine if LTP001 had an adequate clinical profile to warrant further clinical development…
- Trial name
- NCT05135000
- Testing
- LTP001
- Where
- 15 sites in United States, Argentina and 5 more
- Volunteers
- 47 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Arterial Hypertension
Central China Congenital Heart Disease Associated Pulmonary Arterial Hypertension Cohort Study
The study will recruit and follow up patients for five years patients newly diagnosed with congenital heart disease associated pulmonary arterial hypertension(CHD-PAH) from the investigator's hospital.
- Trial name
- CHD-PAHCS (NCT03977428)
- Testing
- standard of care
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Wuhan Asia Heart Hospital
Pulmonary Arterial Hypertension
Clinical Trial of 2-HOBA in Pulmonary Arterial Hypertension
Based on existing literature and clinical trials, 2- hydroxbenzylamine (2-HOBA) has clear impact on mechanisms that much of the international field of pulmonary hypertension (PH) research agrees are central to disease…
- Trial name
- NCT06176118
- Testing
- 2-HOBA
- Volunteers
- 12 people
- Sponsor
- Vanderbilt University Medical Center
Congenital Abnormalities, Pulmonary Arterial Hypertension (PAH)
Safety and Effectiveness of a Virtual Pediatric Cardiac Rehabilitation Program or Telerehabilitation in Children With Heart Disease
Cardiac telerehabilitation is a much-needed pediatric therapy; however, a lack of randomized controlled trials has limited the development of and reimbursement for this valuable service.
- Conditions
- Congenital Abnormalities, Pulmonary Arterial Hypertension (PAH), Orthotopic Heart Transplant, Cardiac Rehabilitation
- Trial name
- NCT06819059
- Testing
- Pediatric Cardiac Telerehabilitation, Fitness Tracker Only
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Columbia University
Pulmonary Arterial Hypertension
Dysregulation of Lipid Metabolism and Right Ventricular Function in PAH
Right ventricular (RV) failure is the predominant cause of death in pulmonary arterial hypertension (PAH). No RV-specific therapies are available, in part because the underlying mechanisms of RV dysfunction are poorly understood.
- Trial name
- NCT02631421
- Testing
- Blood Sampling, Cardiac MRI
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Vanderbilt University
Pulmonary Hypertension
Effect of Inhaled Albuterol in Pulmonary Hypertension
The purpose of the present pilot study is to test the hypothesis that in patients with group 1 pulmonary arterial hypertension (PAH) who are on regular oral pulmonary vasodilator therapy, inhaled albuterol causes transient…
- Trial name
- NCT03270332
- Testing
- Albuterol
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Miami
Pulmonary Arterial Hypertension
Correlation of LONGterm Wrist ACTigraphy Recorded Physical Performance & 6-minute Walk Distance in Patients With Pulmonary Arterial Hypertension
The objective of the study is to monitor physical activity longitudinally with a wrist activity tracker specifically in PAH patients newly initiating ERA therapy and to assess the correlation with the 6MWD at different time…
- Trial name
- LONGACT (NCT02309463)
- Testing
- Endothelin receptor antagonist therapy
- Sponsor
- Actelion
Pulmonary Hypertension, Chronic Thromboembolic Pulmonary Hypertension
Right Atrial Fibrosis in Pulmonary Hypertension
The study aim to assess right atrial (RA) remodeling, in terms of RA fibrosis, in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension patients.
- Conditions
- Pulmonary Hypertension, Chronic Thromboembolic Pulmonary Hypertension, Pulmonary Arterial Hypertension
- Trial name
- RAFE-PH (NCT04663230)
- Testing
- cardiac magnetic resonance imaging
- Where
- 2 sites in Germany
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Giessen
Postpartum Hemorrhage \(PPH\), Postpartum Hemorrhage \(Primary\)
Safety and Effectiveness of the Alma System in Treating Primary Postpartum Hemorrhage
Postpartum Hemorrhage (PPH) is an obstetric emergency that can occur up to 24 hours after vaginal birth or cesarean section. In most cases, the uncontrolled bleeding is due to a lack of sufficient contraction of the uterus…
- Conditions
- Postpartum Hemorrhage \(PPH\), Postpartum Hemorrhage \(Primary\), PPH
- Trial name
- NCT06166771
- Testing
- Alma system
- Where
- Kenya
- Volunteers
- 10 people
- Sponsor
- ResQ Medical Ltd
Hypertension, Pulmonary
A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension
The purpose of this study is to evaluate whether the addition of selexipag to standard of care treatment delays disease progression in children with Pulmonary Arterial Hypertension (PAH) in comparison to placebo.
- Trial name
- SALTO (NCT04175600)
- Testing
- Selexipag, Standard of Care (SOC): Endothelin receptor antagonist, SOC: Phosphodiesterase type 5 (PDE-5) inhibitor
- Where
- 116 sites in United States, Australia and 30 more
- Volunteers
- 138 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
A Pilot Study of Microbiota Transplant With Antibiotic Preconditioning and Fiber Supplementation in Pulmonary Arterial Hypertension (GUT RESTORE-PAH)
This pilot clinical trial will evaluate the initial safety, feasibility, and pharmacokinetics of microbiota transplant therapy (MTT) with antibiotic pre-conditioning and fiber supplementation vs.
- Trial name
- NCT06481852
- Testing
- MTT with antibiotic preconditioning + fiber supplementation
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Minnesota
Sarcoidosis, Pulmonary Arterial Hypertension
Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension
This trial will study the treatment of sarcoidosis-associated pulmonary arterial hypertension with inhaled iloprost, a drug approved for primary pulmonary arterial hypertension.
- Trial name
- NCT00403650
- Testing
- Iloprost
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Cincinnati
Pulmonary Arterial Hypertension
Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso®
The purpose of this multi-center, open-label, safety and tolerability study was to assess the addition of oral treprostinil (UT-15C sustained release [SR] tablets) to subjects currently receiving Tyvaso (treprostinil) inhalation…
- Trial name
- NCT01477333
- Testing
- UT-15C SR, Tyvaso Inhalation Solution
- Where
- 6 sites in United States
- Volunteers
- 18 people
- Sponsor
- United Therapeutics
Portopulmonary Hypertension, Pulmonary Arterial Hypertension (PAH)
Genetic Hallmarks of Patients With Congenital Portosystemic Shunts and Portopulmonary Hypertension
Congenital portosystemic shunt (CPSS) are rare vascular malformations causing blood from the intestines to bypass the liver and directly flow into body's general circulation.
- Conditions
- Portopulmonary Hypertension, Pulmonary Arterial Hypertension (PAH), Congenital Portosystemic Shunt
- Trial name
- Gen-PoPH-CPSS (NCT07314814)
- Testing
- targeted gene panels analysis, whole genome analysis
- Where
- Switzerland
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Prof. Valérie Mc Lin
High Altitude, Healthy Adult
Assessment of Total Pulmonary Resistance sPAP/CO Between High Altitude HA vs. Sea Level LA in Healthy Individuals H
To study the effect of relocation from high altitude (Quito Ecuador: 2850m) to sea level on pulmonary resistance (sPAP/CO) and other hemodynamic outcomes in healthy individuals, who live permanently >2600m.
- Conditions
- High Altitude, Healthy Adult, Echocardiography, Pulmonary Resistance
- Trial name
- NCT07804485
- Testing
- Descent from 2850m to sea level
- Where
- Switzerland
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Silvia Ulrich Somaini